You are here
Grants and Contributions
Grants and Contributions
Advancing Knowledge and Public Health
Pfizer remains committed to supporting programs and initiatives that benefit the public, advance medical care, and improve patient outcomes. Here you will find some general information on grants, funding, and other opportunities that are now available to help improve the lives of patients with rare diseases.
Blocks after Body
Show funding types for these rare disease
Healthcare Charitable Contributions
Pfizer offers funding to qualified 501(c)(3) organizations for certain healthcare-related programs/activities for patients. This type of support is limited to the following: 1) patient education, including health screening; 2) patient advocacy for disease awareness, and 3) patient access to care (e.g., transportation costs).
For purposes of Pfizer's funding of external, independent, not-for-profit organizations, Special Events include, but are not limited to fundraising dinners, walks, biking and golf events, galas, awards ceremonies, and other similar events that do not provide Pfizer with a tangible benefit. Pfizer will not provide input into the content or strategic direction of such Special Events.
Lobbying and Political Contributions
In the highly regulated and competitive pharmaceutical industry, it is crucial to our stakeholders that we engage in public policy issues that may affect our ability to meet patient needs and enhance shareholder value. This site contains information around corporate and employee Political Action Committee contributions.
Research and Education
Independent Grants for Learning & Change
Pfizer offers funding for healthcare quality improvement initiatives, dissemination and implementation (D&I) research, continuing professional development, and other independent education activities for healthcare professionals, including CME/CE (accredited and non-accredited).
Investigator-Initiated Research (IIR)
Pfizer is able to support investigators in conducting their own research by providing funding for pre-clinical, early clinical, and late clinical research through the Investigator-Initiated Research program
Global Compound Transfer Program
Pfizer is able to provide support to investigators for in vitro or animal studies requesting pure compound only and do not require study funding.
Rare Disease Consortium (RDC)
The RDC aims to identify novel science in the rare disease space and to build true Pfizer/Academic drug discovery collaborations with the aspiration to make a medicine for the future treatment of rare diseases.
Advancing Science through Pfizer - Investigator Research Exchange (ASPIRE)
The ASPIRE program is a competitive grants program sponsored by Pfizer for young and established scientists. ASPIRE seeks to support basic science, translational, and clinical research that advances medical knowledge in the pathogenesis, treatment, and prevention of selected diseases.